男性人工尿道括约肌植入:基于法国国家医疗数据系统的再干预评估研究
该回顾性队列纳入2006至2018年法国8475例因前列腺癌或良性前列腺增生治疗后压力性尿失禁行首次人工尿道括约肌植入的男性,中位随访6年,2年、5年、10年无再干预生存率分别为71%、57%、40%,中位再干预时间6.6年,再干预概率2年内为29%。
要点
- 首次人工尿道括约肌植入后2年无再干预生存率为71%,5年为57%,10年为40%。
- 2年内再干预概率为29%,中位再干预时间为6.6年。
- 良性前列腺增生术后、放疗联合根治性前列腺切除术后及植入量较少的中心再干预风险更高。
核心结论
- 因前列腺癌或良性前列腺增生治疗后继发压力性尿失禁而行人工尿道括约肌植入的男性中,2年内再干预概率为29%,10年无再干预生存率为40%,中位再干预时间为6.6年。
- 上述结果可为男压力性尿失禁管理中患者和外科医生的治疗决策提供信息。
研究设计与样本
- 基于法国国家医疗数据系统的回顾性队列研究,纳入2006年1月1日至2018年12月31日期间因前列腺癌或良性前列腺增生治疗后压力性尿失禁行首次人工尿道括约肌植入的18岁及以上男性,共8475例。
- 采用Kaplan-Meier法估计无再干预生存率,并用多变量Cox比例风险模型评估患者和医院因素与再干预风险的关联。
主要发现
- 纳入8475例男性,中位年龄69岁(IQR 65-74),中位随访时间6年(IQR 3-9)。
- 无再干预生存率2年为71%(95%CI 70-72),5年为57%(95%CI 55-58),10年为40%(95%CI 38-41)。
- 无取出生存率2年为83%(95%CI 83%-84%),5年为75%(95%CI 74%-76%),10年为66%(95%CI 65%-68%)。
- 良性前列腺增生术后、放疗联合根治性前列腺切除术后及植入量较少的中心,无再干预生存率更低。
- 2年内再干预概率为29%,中位再干预时间6.6年(IQR 6.4-7.1)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Significant concerns remain regarding the long-term outcomes of American Medical Systems 800 artificial urinary sphincter (AUS) implants in men. The objective was to assess the long-term AUS reintervention (replacement or removal) rates after a first-ever AUS implantation. MATERIALS AND METHODS: This population-based retrospective cohort study included all men age ≥ 18 years in France who underwent a first-ever AUS implantation (identified using a unique device identifier) for male stress urinary incontinence (SUI) after prostate cancer or benign prostatic hyperplasia (BPH) treatment, between January 1, 2006, and December 31, 2018. The primary outcome was reintervention-free survival rates (replacements and removals), estimated using the Kaplan-Meier method. Secondary outcomes were replacement and removal. A multivariable Cox proportional hazards model was used to assess associations between patient and hospital factors and the hazard of reintervention. RESULTS: The study included 8475 men with a median age of 69 years (IQR, 65-74) and a median follow-up time of 6 years (IQR, 3-9). Reintervention-free survival was 71% (95% CI, 70-72) at 2 years, 57% (95% CI, 55-58) at 5 years, and 40% (95% CI, 38-41) at 10 years. Reintervention-free survival was lower after BPH surgery, after radiotherapy combined with radical prostatectomy, and in centers performing fewer implantations. Removal-free survival was 83% (95% CI, 83%-84%) at 2 years, 75% (95% CI, 74%-76%) at 5 years, and 66% (95% CI, 65%-68%) at 10 years. CONCLUSIONS: Among men undergoing AUS implantation for SUI because of prostate cancer or BPH treatment, the probability of reintervention was 29% within 2 years after implantation. The median time to reintervention was 6.6 years (IQR, 6.4-7.1), and the reintervention-free survival rate at 10 years was 40%. These insights can inform therapeutic decision-making for patients and surgeons during the management of male SUI.
引用
- Lenfant L, Taillé Y, Chartier-Kastler E, et al. Artificial Urinary Sphincter Implants in Men: A National Health Care Data System-Based Study to Assess Reinterventions in France. J Urol. 2024. PMID: 39401342. doi:10.1097/JU.0000000000004285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。